Condensed Consolidated Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
| Income Statement [Abstract] | ||||
| SALES | $ 252,940 | $ 171,383 | $ 356,770 | $ 416,178 |
| COST OF SALES (excluding depreciation expense) | 65,638 | 30,230 | 106,307 | 86,367 |
| GROSS PROFIT | 187,302 | 141,153 | 250,463 | 329,811 |
| OPERATING EXPENSES: | ||||
| Compensation and related benefits (including stock-based compensation of $272,648 and $913,348 for the three months ended September 30, 2020 and 2019, and $942,850 and $3,392,522 for the nine months ended September 30, 2020 and 2019, respectively) | 628,701 | 1,252,366 | 2,234,525 | 4,573,248 |
| Research and development | 9,868 | 3,525 | 14,597 | 23,925 |
| Professional fees | 117,065 | 171,882 | 404,145 | 681,986 |
| General and administrative expenses | 97,126 | 106,628 | 279,601 | 352,962 |
| Total Operating Expenses | 852,760 | 1,534,401 | 2,932,868 | 5,632,121 |
| LOSS FROM OPERATIONS | (665,458) | (1,393,248) | (2,682,405) | (5,302,310) |
| OTHER INCOME (EXPENSES): | ||||
| Gain on debt extinguishment, net | 767,415 | 31,009 | 877,823 | 31,009 |
| Other income | 8,000 | |||
| Derivative income (expense) | 653,405 | (381,005) | (90,623) | (381,005) |
| Interest expense | (274,966) | (58,421) | (732,547) | (171,060) |
| Total Other Income (Expenses) | 1,145,854 | (408,417) | 62,653 | (521,056) |
| NET (LOSS) INCOME | 480,396 | (1,801,665) | (2,619,752) | (5,823,366) |
| PREFERRED STOCK DIVIDEND | (2,795) | (2,795) | ||
| NET (LOSS) INCOME ATTRIBUTABLE TO COMMON SHAREHOLDERS | $ 477,601 | $ (1,801,665) | $ (2,622,547) | $ (5,823,366) |
| NET (LOSS) INCOME PER COMMON SHARE: | ||||
| Basic and diluted | $ 0 | $ (0.02) | $ (0.02) | $ (0.07) |
| WEIGHTED AVERAGE COMMON SHARE OUTSTANDING: | ||||
| Basic and diluted | 201,624,719 | 102,189,132 | 155,441,343 | 88,146,289 |
| X | ||||||||||
- Definition Derivative expense. No definition available.
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of expense for employee benefit and equity-based compensation. No definition available.
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of income related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|
| X | ||||||||||
- References No definition available.
|